Adenosine-associated delivery systems

References

• Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33–9
   PubMed Web of Science ®Google Scholar
• Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 2003;69:313–40
   PubMed Web of Science ®Google Scholar
• Agteresch HJ, Dagnelie PC, van den Berg JWO, Wilson JHP. Adenosine triphosphate – established and potential clinical applications. Drugs 1999;58:211–32
   PubMed Web of Science ®Google Scholar
• Faulds D, Chrisp P, Buckley MMT. Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia. Drugs 1991;41:596–624
   PubMed Web of Science ®Google Scholar
• Mendonça Ad, Sebastião AM, Ribeiro JA. Adenosine: does it have a neuroprotective role after all? Brain Res Rev 2000;33:258–74
   PubMed Web of Science ®Google Scholar
• Wojcik WJ, Neff NH. Adenosine measurement by a rapid HPLC-fluorometric method: induced changes of adenosine content in regions of rat brain. J Neurochem 1982;39:280–2
   PubMed Web of Science ®Google Scholar
• Bjorklund A. Cell replacement strategies for neurodegenerative disorders. Novartis Found Symp 2000;231:7–15
   PubMed Web of Science ®Google Scholar
• Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 2004;240:31–304
   PubMed Web of Science ®Google Scholar
• Hoebertz A, Arnett TR, Burnstock G. Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci 2003;24:290–7
   PubMed Web of Science ®Google Scholar
• Paidas CN, Dudgeon DL, Haller JA, Clemens MG. Adenosine triphosphate (ATP) treatment of hypoxic pulmonary hypertension (HPH): comparison of dose dependence in pulmonary and renal circulations. J Surg Res 1989;46:374–9
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Haydon PG, Yeung ES. Direct observation of calcium-independent intercellular ATP signaling in astrocytes. Analyt Chem 2000;72:2001–7
   PubMed Web of Science ®Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, et al. Nomenclature and classification of adenosine receptors – an update. Pharmacol Rev 2011;63:1–34
   PubMed Web of Science ®Google Scholar
• Fredholm BB. Adenosine – a physiological or pathophysiological agent? J Mol Med 2014;92:201–6
   PubMed Web of Science ®Google Scholar
• Ecke D, Fischer B, Reiser G. Diastereoselectivity of the P2Y11 nucleotide receptor: mutational analysis. Br J Pharmacol 2008;155:1250–5
   PubMed Web of Science ®Google Scholar
• Guo D, von Kügelgen I, Moro S, et al. Evidence for the recognition of non-nucleotide antagonists within the transmembrane domains of the human P2Y1 receptor. Drug Dev Res 2012;57:173–81
   Google Scholar
• Tosh DK, Phan K, Deflorian F, et al. Truncated (N)-methanocarba nucleosides as A1 adenosine receptor agonists and partial agonists: overcoming lack of a recognition element. ACS Med Chem Lett 2011;2:626–31
   PubMed Web of Science ®Google Scholar
• Wang Z, Do CW, Avila MY, et al. Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. Exp Eye Res 2010;90:146–54
   PubMed Web of Science ®Google Scholar
• Ballesteros JA, Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 1995;25:366–428
   Google Scholar
• Mao Y, Zhang L, Jin J, et al. Mutational analysis of residues important for ligand interaction with the human P2Y12 receptor. Eur J Pharmacol 2010;644:10–16
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Balasubramanian R, Deflorian F, Gao ZG. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. Purinergic Signal 2012;8:419–36
   PubMed Web of Science ®Google Scholar
• Dawson RMC. Data for biochemical research. 3rd ed. Oxford: Oxford University Press; 1986
   Google Scholar
• Gabrielian AG. Solubility of adenosine in concentrated salt solutions. Biofizika 1977;22:789–93
   PubMed Web of Science ®Google Scholar
• Drury AN, Szent-Györgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 1929;68:213–37
   PubMedGoogle Scholar
• Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res 1980;47:807–13
   PubMed Web of Science ®Google Scholar
• Pak K, Zsuga J, Kepes Z, et al The effect of adenosine deaminase inhibition on the A1 adenosinergic and M 2 muscarinergic control of contractility in eu- and hyperthyroid guinea pig atria. Naunyn – Schmiedeberg's Arch Pharmacol 2015. [Epub ahead of print]. doi: 10.1007/s00210-015-1121-6
   Google Scholar
• U.S. Food and Drug Administration. FDA warns of rare but serious risk of heart attack and death with cardiac nuclear stress test drugs Lexiscan (regadenoson) and Adenoscan (adenosine). Silver Spring (MD): US FDA; 2013
   Google Scholar
• Dunwiddie TV. Adenosine and suppression of seizures. Adv Neurol 1999;79:1001–10
   PubMedGoogle Scholar
• Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol 2009;53:709–17
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration/Center for Drug Evaluation and Research. Adenosine. Silver Spring (MD): US FDA; 2015
   Google Scholar
• U.S. Food and Drug Administration. Adenocard IV (adenosine injection) for rapid bolus intravenous use. Silver Spring, MD: US FDA; 2005
   Google Scholar
• U.S. Food and Drug Administration. Adenoscan® (adenosine injection) for intravenous infusion only. Silver Spring, MD: US FDA; 2009
   Google Scholar
• Adenosine-FDA prescribing information. Available from: http://www.drugs.com/pro/adenosine.html [last accessed June 2015]
   Google Scholar
• Melemedjian OK, Asiedu MN, Tillu DV, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain 2011;7:70
   PubMed Web of Science ®Google Scholar
• Tsutsui S, Schnermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004;24:1521–9
   PubMed Web of Science ®Google Scholar
• Pelner L, Waldman S. The use of adenosine-5-monophosphate in the treatment of acute subdeltoid bursitis. N Y State J Med 1952;52:1774–6
   PubMedGoogle Scholar
• Rottino A. Adenosine-5-monophosphate in the treatment of tendinitis. J Lancet 1951;71:237–8
   PubMedGoogle Scholar
• Zylka MJ. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 2011;17:188–96
   PubMed Web of Science ®Google Scholar
• Raffetto JD, Yu P, Reslan OM, et al. Endothelium-dependent nitric oxide and hyperpolarization-mediated venous relaxation pathways in rat inferior vena cava. J Vasc Surg 2012;55:1716–25
   PubMed Web of Science ®Google Scholar
• Schmidt C, Gavoille R, Perez P, Schmitt J. Double-blind plethysmographic study of venous effects of heptaminol adenosine phosphate in patients with primary varicose veins. Eur J Clin Pharmacol 1989;37:37–40
   PubMed Web of Science ®Google Scholar
• Lynch ME, Clark AJ, Sawynok J. Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrolment design. Pain 2003;103:111–17
   PubMed Web of Science ®Google Scholar
• Sklar SH, Buimoviciklein E. Adenosine in the treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 1979;48:416–17
   Web of Science ®Google Scholar
• Ma Y, He B. Recognition of herpes simplex viruses: toll-like receptors and beyond. J Mol Biol 2014;426:1133–47
   PubMed Web of Science ®Google Scholar
• Sklar SH, Blue WT, Alexander EJ, Bodian CA. Herpes zoster. The treatment and prevention of neuralgia with adenosine monophosphate. JAMA 1985;253:1427–30
   PubMed Web of Science ®Google Scholar
• Handler CE, Fray R, Perkin GD, Woinarski J. Radiculomyelopathy associated with herpes simplex genitalis treated with adenosine arabinoside. Postgrad Med J 1983;59:388–9
   PubMed Web of Science ®Google Scholar
• Hofmann F, Beavo JA, Bechtel PJ, Krebs EG. Comparison of adenosine 3':5'-monophosphate-dependent protein kinases from rabbit skeletal and bovine heart muscle. J Biol Chem 1975;250:7795–801
   PubMed Web of Science ®Google Scholar
• Gajdos A. Letter: A.M.P. in porphyria cutanea tarda. Lancet 1974;1:163
   PubMedGoogle Scholar
• Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515–22
   PubMed Web of Science ®Google Scholar
• Sollevi A, Lagerkranser M, Irestedt L, et al. Controlled hypotension with adenosine in cerebral aneurysm surgery. Anesthesiology 1984;61:400–5
   PubMed Web of Science ®Google Scholar
• Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:321–8
   PubMed Web of Science ®Google Scholar
• Arthur E. Baue EF, Donald E. Fry. Multiple organ failure: pathophysiology, prevention, and therapy. New York: Springer;2000;88:712
   Google Scholar
• Khal J, Hine AV, Fearon KCH, et al. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005;37:2196–206
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004;66:480–5
   PubMed Web of Science ®Google Scholar
• Hyde SC, Emsley P, Hartshorn MJ, et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990;346:362–5
   PubMed Web of Science ®Google Scholar
• Feigl EO. Berne's adenosine hypothesis of coronary blood flow control. Am J Physiol Heart Circ Physiol 2004;287:1891–4
   Google Scholar
• Padykula HA, Herman E. The specificity of the histochemical method for adenosine triphosphatase. J Histochem Cytochem 1955;3:170–95
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Q, Wan R, et al. Intracellular adenosine triphosphate delivery enhanced skin wound healing in rabbits. Ann Plast Surg 2009;62:180–6
   PubMed Web of Science ®Google Scholar
• Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992;78:43–8
   Web of Science ®Google Scholar
• Belardinelli L. Adenosine system in the heart. Drug Dev Res 2004;28:263–7
   Google Scholar
• Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci 2006;27:652–8
   PubMed Web of Science ®Google Scholar
• Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315–23
   PubMed Web of Science ®Google Scholar
• Boison D. Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 2007;5:115–25
   PubMed Web of Science ®Google Scholar
• Boison D, Stewart KA. Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation. Biochem Pharmacol 2009;78:1428–37
   PubMed Web of Science ®Google Scholar
• McNamara JO. Emerging insights into the genesis of epilepsy. Nature 1999;399:A15–22
   Google Scholar
• Vajda FJE. Pharmacotherapy of epilepsy: new armamentarium, new issues. J Clin Neurosci 2007;14:813–23
   PubMed Web of Science ®Google Scholar
• Boison D, Huber A, Padrun V, et al. Seizure suppression by adenosine-releasing cells is independent of seizure frequency. Epilepsia 2002;43:788–96
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Chen JF, Cunha RA, et al. Adenosine and brain function. Int Rev Neurobiol 2005;63:191–270
   PubMed Web of Science ®Google Scholar
• Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990;70:761–845
   PubMed Web of Science ®Google Scholar
• Johnston-Cox HA, Ravid K. Adenosine and blood platelets. Purinergic Signal 2011;7:357–65
   PubMed Web of Science ®Google Scholar
• Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24:116–47
   PubMed Web of Science ®Google Scholar
• Pagonopoulou O, Efthimiadou A, Asimakopoulos B, Nikolettos NK. Modulatory role of adenosine and its receptors in epilepsy: possible therapeutic approaches. Neurosci Res 2006;56:14–20
   PubMed Web of Science ®Google Scholar
• Cieslak M, Komoszyński M, Wojtczak A. Adenosine A2A receptors in Parkinson’s disease treatment. Purinergic Signal 2008;4:305–12
   PubMed Web of Science ®Google Scholar
• Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759–70
   PubMed Web of Science ®Google Scholar
• Sachdeva S, Gupta M. Adenosine and its receptors as therapeutic targets: an overview. Saudi Pharm J 2013;21:245–53
   Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818–22
   PubMed Web of Science ®Google Scholar
• Dash AK, Cudworth GC. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40:1–12
   PubMed Web of Science ®Google Scholar
• Langer R. Drug delivery and targeting. Nature 1998;392:5–10
   PubMed Web of Science ®Google Scholar
• Peppas NA, Hilt JZ, Khademhosseini A, Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv Mater 2006;18:1345–60
   Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161–71
   PubMed Web of Science ®Google Scholar
• Naahidi S, Jafari M, Edalat F, et al. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 2013;166:182–94
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008;8:473–80
   PubMed Web of Science ®Google Scholar
• Kazemzadeh-Narbat M, Kindrachuk J, Duan K, et al. Antimicrobial peptides on calcium phosphate-coated titanium for the prevention of implant-associated infections. Biomaterials 2010;31:9519–26
   PubMed Web of Science ®Google Scholar
• Kazemzadeh-Narbat M, Noordin S, Masri BA, et al. Drug release and bone growth studies of antimicrobial peptide – loaded calcium phosphate coating on titanium. J Biomed Mater Res B Appl Biomater 2012;100:1344–52
   PubMed Web of Science ®Google Scholar
• Kazemzadeh-Narbat M, Lai BFL, Ding C, et al. Multilayered coating on titanium for controlled release of antimicrobial peptides for the prevention of implant-associated infections. Biomaterials 2013;34:5969–77
   PubMed Web of Science ®Google Scholar
• Kazemzadeh-Narbat M, Wang Q, Duan K, et al. Antimicrobial peptide delivery from trabecular bone grafts. J Biomater Tissue Eng 2014;4:967–72
   Web of Science ®Google Scholar
• Kazemzadeh-Narbat M, Annabi N, Khademhosseini A. Surgical sealants and high strength adhesives. Mater Today 2015;18:176–7
   Web of Science ®Google Scholar
• Ma M, Kazemzadeh-Narbat M, Hui Y, et al. Local delivery of antimicrobial peptides using self-organized TiO2 nanotube arrays for peri – implant infections. J Biomed Mater Res A 2012;100:278–85
   PubMed Web of Science ®Google Scholar
• Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci 2001;90:667–80
   PubMed Web of Science ®Google Scholar
• Xu GX, Xie XH, Liu FY, et al. Adenosine triphosphate liposomes: encapsulation and distribution studies. Pharm Res 1990;7:553–7
   PubMed Web of Science ®Google Scholar
• Gomes I, Sharma SK. Uptake of liposomally entrapped adenosine-3′-5′-cyclic monophosphate in mouse brain. Neurochem Res 2004;29:441–6
   PubMed Web of Science ®Google Scholar
• Chiang B, Essick E, Ehringer W, et al. Enhancing skin wound healing by direct delivery of intracellular adenosine triphosphate. Am J Surg 2007;193:213–18
   PubMed Web of Science ®Google Scholar
• Chien S. Intracellular ATP delivery using highly fusogenic liposomes. Methods Mol Biol 2010;605:377–91
   PubMedGoogle Scholar
• Ware JA, Smith M, Salzman EW. Synergism of platelet-aggregating agents. Role of elevation of cytoplasmic calcium. J Clin Invest 1987;80:267–71
   Google Scholar
• Okamura Y, Katsuno S, Suzuki H, et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute. J Control Release 2010;148:373–9
   PubMed Web of Science ®Google Scholar
• Orive G, Anitua E, Pedraz JL, Emerich DF. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 2009;10:682–92
   PubMed Web of Science ®Google Scholar
• Lainka E, Hershfield MS, Santisteban I, et al. Polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency. Clin Diagn Lab Immunol 2005;12:861–6
   PubMedGoogle Scholar
• Hooftman G, Herman S, Schacht E. Poly(ethylene glycol)s with reactive endgroups. 2. Practical consideration for the preparation of protein-PEG conjugates. J Bioact Compat Polym 1996;11:135–59
   Web of Science ®Google Scholar
• Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. Angew ChemInt Ed 2010;49:6288–308
   PubMed Web of Science ®Google Scholar
• Davis S, Abuchowski A, Park YK, Davis FF. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 1981;46:649–52
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451–8
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Sriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. New York (NY): McGraw-Hill; 1995
   Google Scholar
• Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 2009;3:349–58
   PubMedGoogle Scholar
• Hershfield MS. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Sem Hematol 1998;35:291–8
   PubMed Web of Science ®Google Scholar
• Levy Y, Hershfield MS, Fernandezmejia C, et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr 1988;113:312–17
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Adminstration. ADAGEN® (pegademase bovine) Injection. Silver Spring, MD: US FDA; 1990
   Google Scholar
• Hershfield MS, Buckley RH, Buckley RH, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316:589–96
   PubMed Web of Science ®Google Scholar
• Bory C, Boulieu R, Souillet G, Hershfield MS. Polyethylene glycol adenosine deaminase a new adenosine deaminase deficiency therapy interest of deoxy ATP determination for therapeutic monitoring. Therapie 1991;46:323–6
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain Md Fau, Fairbanks LD, et al. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. Br J Haematol 2000;109:549–54
   PubMed Web of Science ®Google Scholar
• Zoghbi WA, Cheirif J, Kleiman NS, et al. Diagnosis of ischemic heart disease with adenosine echocardiography. J Am Coll Cardiol 1991;18:1271–9
   PubMed Web of Science ®Google Scholar
• Horwitz LD, Kaufman D, Keller MW, Kong YO. Time course of coronary endothelial healing after injury due to ischemia and reperfusion. Circulation 1994;90:2439–47
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88:11460–4
   PubMed Web of Science ®Google Scholar
• Tissier R, Cohen MV, Downey JM. Protecting the acutely ischemic myocardium beyond reperfusion therapies: are we any closer to realizing the dream of infarct size elimination? Arch Mal Coeur Vaiss 2007;100:794–802
   PubMedGoogle Scholar
• Lee KY, Ha WS, Park WH. Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 1995;16:1211–16
   PubMed Web of Science ®Google Scholar
• Nishimura K, Ishihara C, Ukei S, et al. Stimulation of cytokine production in mice using deacetylated chitin. Vaccine 1986;4:151–6
   PubMed Web of Science ®Google Scholar
• Xiu Liang Z, Yong Zhong D, Ri Sheng Y, et al. Galactosylated chitosan oligosaccharide nanoparticles for hepatocellular carcinoma cell-targeted delivery of adenosine triphosphate. Int J Mol Sci 2013;14:15755–66
   PubMed Web of Science ®Google Scholar
• Chung TW, Yang J, Akaike T, et al. Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment. Biomaterials 2002;23:2827–34
   PubMed Web of Science ®Google Scholar
• Kang Y, Wang C, Liu K, et al. Enzyme-responsive polymeric supra-amphiphiles formed by the complexation of chitosan and ATP. Langmuir 2012;28:14562–6
   PubMed Web of Science ®Google Scholar
• Kazemzadeh-Narbat M, Reid M, Brooks MS, Ghanem A. Chitosan nanoparticles as adenosine carriers. J Microencapsul 2015. [Epub ahead of print]. doi: 10.3109/02652048.2015.1046517
   PubMed Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar M. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004;21:387–422
   PubMed Web of Science ®Google Scholar
• Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems – a review. Int J Pharm 2011;415:34–52
   PubMed Web of Science ®Google Scholar
• Muller CE. Adenosine receptor ligands-recent developments part I. Agonists. Curr Med Chem 2000;7:1269–88
   PubMed Web of Science ®Google Scholar
• Simpson RE, O'Regan Mh, Perkins LM, Phillis JW. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists. J Neurochem 1992;58:1683–90
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Scatturin A, Pavan B, et al. Poly(lactic acid) microspheres for the sustained release of a selective A1 receptor agonist. J Control Release 2001;73:303–13
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Leo E, Vitali F, et al. Development and characterization of biodegradable nanospheres as delivery systems of anti-ischemic adenosine derivatives. Biomaterials 2005;26:1299–306
   PubMed Web of Science ®Google Scholar
• Maquet V, Martin D, Scholtes F, et al. Poly(d,l-lactide) foams modified by poly(ethylene oxide)–block–poly(d,l-lactide) copolymers and a-FGF: in vitro and in vivo evaluation for spinal cord regeneration. Biomaterials 2001;22:1137–46
   PubMed Web of Science ®Google Scholar
• Rooney GE, Knight Am, Madigan NN, et al. Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo [(polyethylene glycol) fumarate] hydrogels. Tissue Eng Part A 2011;17:1287–302
   PubMed Web of Science ®Google Scholar
• De Boer R, Knight AM, Spinner RJ, et al. In vitro and in vivo release of nerve growth factor from biodegradable poly-lactic-co-glycolic-acid microspheres. J Biomed Mater Res A 2010;95:1067–73
   PubMedGoogle Scholar
• Boison D, Scheurer L, Tseng JL, et al. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp Neurol 1999;160:164–74
   PubMed Web of Science ®Google Scholar
• McNamara JO, Bonhaus DW, Shin C, et al. The kindling model of epilepsy: a critical review. CRC Crit Rev Clin Neurobiol 1985;1:341–91
   PubMedGoogle Scholar
• Horan RL, Antle K, Collette AL, et al. In vitro degradation of silk fibroin. Biomaterials 2005;26:3385–93
   PubMed Web of Science ®Google Scholar
• Wenk E, Merkle HP, Meinel L. Silk fibroin as a vehicle for drug delivery applications. J Control Release 2011;150:128–41
   PubMed Web of Science ®Google Scholar
• Szybala C, Pritchard EM, Lusardi TA, et al. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp Neurol 2009;219:126–35
   PubMed Web of Science ®Google Scholar
• Wilz A, Pritchard EM, Li T, et al. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 2008;29:3609–16
   PubMed Web of Science ®Google Scholar
• Wang X, Wenk E, Hu X, et al. Silk coatings on PLGA and alginate microspheres for protein delivery. Biomaterials 2007;28:4161–9
   PubMed Web of Science ®Google Scholar
• Kim UJ, Park J, Kim HJ, et al. Three-dimensional aqueous-derived biomaterial scaffolds from silk fibroin. Biomaterials 2005;26:2775–85
   PubMed Web of Science ®Google Scholar
• Hofmann S, Foo C, Rossetti F, et al. Silk fibroin as an organic polymer for controlled drug delivery. J Control Release 2006;111:219–27
   PubMed Web of Science ®Google Scholar
• Wang XQ, Wenk E, Matsumoto A, et al. Silk microspheres for encapsulation and controlled release. J Control Release 2007;117:360–70
   PubMed Web of Science ®Google Scholar
• Ren G, Li T, Lan JQ, et al. Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol 2007;208:26–37
   PubMed Web of Science ®Google Scholar
• Pritchard EM, Kaplan DL. Silk fibroin biomaterials for controlled release drug delivery. Expert Opin Drug Deliv 2011;8:797–811
   PubMed Web of Science ®Google Scholar
• Pritchard EM, Szybala C, Boison D, Kaplan DL. Silk fibroin encapsulated powder reservoirs for sustained release of adenosine. J Control Release 2010;144:159–67
   PubMed Web of Science ®Google Scholar
• Masino S, Boison D. Adenosine, a key link between metabolism and brain activity. Berlin: Springer; 2013
   Google Scholar
• Wang Y, Rudym DD, Walsh A, et al. In vivo degradation of three-dimensional silk fibroin scaffolds. Biomaterials 2008;29:3415–28
   PubMed Web of Science ®Google Scholar
• Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997;277:1232–7
   Web of Science ®Google Scholar
• Riva ER, Desii A, Sartini S, et al. PMMA/polysaccharides nanofilm loaded with adenosine deaminase inhibitor for targeted anti-inflammatory drug delivery. Langmuir 2013;29:13190–7
   PubMed Web of Science ®Google Scholar
• Ye JH, Rajendran VM. Adenosine: an immune modulator of inflammatory bowel diseases. World J Gastroenterol 2009;15:4491–8
   PubMed Web of Science ®Google Scholar
• Sayari A, Hamoudi S. Periodic mesoporous silica-based organic – inorganic nanocomposite materials. Chem Mater 2001;13:3151–68
   Web of Science ®Google Scholar
• Stein A, Melde BJ, Schroden RC. Hybrid inorganic-organic mesoporous silicates – nanoscopic reactors coming of age. Adv Mater 2000;12:1403–19
   Web of Science ®Google Scholar
• Gruenhagen JA, Lai CY, Radu DR, et al. Real-time imaging of tunable adenosine 5-triphosphate release from an MCM-41-type mesoporous silica nanosphere-based delivery system. Appl Spectrosc 2005;59:424–31
   PubMed Web of Science ®Google Scholar
• Lai CY, Trewyn BG, Jeftinija DM, et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc 2003;125:4451–9
   PubMed Web of Science ®Google Scholar
• Chan WCW, Nie SM. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998;281:2016–18
   PubMed Web of Science ®Google Scholar
• Dorey E. Cell based delivery. Nat Biotechnol 2001;19:BE11
   Google Scholar
• Boison D. Adenosine-based cell therapy approaches for pharmacoresistant epilepsies. Neurodegen Dis 2007;4:28–33
   PubMed Web of Science ®Google Scholar
• Loscher W, Gernert M, Heinemann U. Cell and gene therapies in epilepsy – promising avenues or blind alleys? Trends Neurosci 2008;31:62–73
   PubMed Web of Science ®Google Scholar
• Raedt R, Van Dycke A, Vonck K, Boon P. Cell therapy in models for temporal lobe epilepsy. Seizure 2007;16:565–78
   PubMed Web of Science ®Google Scholar
• Shetty AK, Hattiangady B. Concise review: prospects of stem cell therapy for temporal lobe epilepsy. Stem Cells 2007;25:2396–407
   PubMed Web of Science ®Google Scholar
• Vezzani A. The promise of gene therapy for the treatment of epilepsy. Expert Rev Neurother 2007;7:1685–92
   PubMedGoogle Scholar
• Huber A, Padrun V, Deglon N, et al. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci USA 2001;98:7611–16
   PubMed Web of Science ®Google Scholar
• Li T, Steinbeck JA, Lusardi T, et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 2007;130:1276–88
   PubMed Web of Science ®Google Scholar
• Li T, Ren G, Lusardi T, et al. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. JClin Invest 2008;118:571–82
   PubMed Web of Science ®Google Scholar
• Boison D, Scheurer L, Zumsteg V, et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci USA 2002;99:6985–90
   PubMed Web of Science ®Google Scholar
• Guttinger M, Fedele D, Koch P, et al. Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. Epilepsia 2005;46:1162–9
   PubMed Web of Science ®Google Scholar
• Guttinger M, Padrun V, Pralong WF, Boison D. Seizure suppression and lack of adenosine A(1) receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp Neurol 2005;193:53–64
   PubMed Web of Science ®Google Scholar
• Hughes M, Vassilakos A, Andrews DW, et al. Delivery of a secretable adenosine deaminase through microcapsules – a novel approach to somatic gene therapy. Hum Gene Ther 1994;5:1445–55
   PubMed Web of Science ®Google Scholar
• Fedele DE, Koch P, Scheurer L, et al. Engineering embryonic stem cell derived glia for adenosine delivery. Neurosci Lett 2004;370:160–5
   PubMed Web of Science ®Google Scholar
• Wu C, Chang A, Smith MC, et al. Beta 4 tubulin identifies a primitive cell source for oligodendrocytes in the mammalian brain. J Neurosci 2009;29:7649–57
   PubMed Web of Science ®Google Scholar
• Boison D. Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res 2009;85:131–41
   PubMed Web of Science ®Google Scholar
• Ruschenschmidt T, Koch PG, Brustle O, Beck H. Functional properties of ES cell-derived neurons engrafted into the hippocampus of adult normal and chronically epileptic rats. Epilepsia 2005;46:174–83
   PubMed Web of Science ®Google Scholar
• Studer FE, Fedele De, Marowsky A, et al. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006;142:125–37
   PubMed Web of Science ®Google Scholar
• Van Dycke A, Verstraete A, Pil K, et al. Quantitative analysis of adenosine using liquid chromatography/atmospheric pressure chemical ionization-tandem mass spectrometry (LC/APCI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1493–8
   PubMed Web of Science ®Google Scholar
• Rebola N, Coelho JE, Costenla AR, et al. Decrease of adenosine A(1) receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur J Neurosci 2003;18:820–8
   PubMed Web of Science ®Google Scholar
• Van Dycke A, Raedt R, Dauwe I, et al. Continuous local intrahippocampal delivery of adenosine reduces seizure frequency in rats with spontaneous seizures. Epilepsia 2010;51:1721–8
   PubMed Web of Science ®Google Scholar
• Uebersax L, Fedele DE, Schumacher C, et al. The support of adenosine release from adenosine kinase deficient ES cells by silk substrates. Biomaterials 2006;27:4599–607
   PubMed Web of Science ®Google Scholar
• Boison D. Engineered adenosine-releasing cells for epilepsy therapy: human mesenchymal stem cells and human embryonic stem cells. Neurotherapeutics 2009;6:278–83
   PubMed Web of Science ®Google Scholar
• Li T, Ren G, Kaplan DL, Boison D. Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. Epilepsy Res 2009;84:238–41
   PubMed Web of Science ®Google Scholar
• LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;21:1184–91
   PubMed Web of Science ®Google Scholar
• Van Dycke A, Raedt R, Verstraete A, et al. Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery. Seizure 2010;19:390–6
   PubMed Web of Science ®Google Scholar
• Lexmond AJ, Hagedoorn P, van der Wiel E, et al. Adenosine dry powder inhalation for bronchial challenge testing, part 1: inhaler and formulation development and in vitro performance testing. Eur J Pharm Biopharm 2014;86:105–14
   PubMed Web of Science ®Google Scholar
• Gutman RL, Peacock G, Lu DR. Targeted drug delivery for brain cancer treatment. J Control Release 2000;65:31–41
   PubMed Web of Science ®Google Scholar
• Maysinger D, Morinville A. Drug delivery to the nervous system. Trends Biotechnol 1997;15:410–18
   PubMed Web of Science ®Google Scholar
• Menei P, Daniel V, Monteromenei C, et al. Biodegradation and brain tissue reaction to poly(d,l-lactide-co-glycolide) microspheres. Biomaterials 1993;14:470–8
   PubMed Web of Science ®Google Scholar
• Lothman EW, Williamson JM. Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapidly developing, transient kindling and a slowly developing, enduring kindling. Brain Res 1994;649:71–84
   PubMed Web of Science ®Google Scholar
• Raedt R, Van Dycke A, Waeytens A, et al. Unconditioned adult-derived neurosphere cells mainly differentiate towards astrocytes upon transplantation in sclerotic rat hippocampus. Epilepsy Res 2009;87:148–59
   PubMed Web of Science ®Google Scholar
• Turner DA, Shetty AK. Clinical prospects for neural grafting therapy for hippocampal lesions and epilepsy. Neurosurgery 2003;52:632–41
   PubMed Web of Science ®Google Scholar
• Zaman V, Turner DA, Shetty AK. Prolonged postlesion transplantation delay adversely influences survival of both homotopic and heterotopic fetal hippocampal cell grafts in kainate-lesioned CA3 region of adult hippocampus. Cell Transpl 2001;10:41–52
   PubMed Web of Science ®Google Scholar
• Galiano RD, Michaels J, Dobryansky M, et al. Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen 2004;12:485–92
   PubMed Web of Science ®Google Scholar
• Barcia JA, Gallego JM. Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model. Neurotherapeutics 2009;6:337–43
   PubMed Web of Science ®Google Scholar
• Wang PP, Frazier J, Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002;54:987–1013
   PubMed Web of Science ®Google Scholar
• Elger CE, Lehnertz K. Seizure prediction by non-linear time series analysis of brain electrical activity. Eur J Neurosci 1998;10:786–9
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami AM, Hancock MJ, Harrington H, et al. Biomimetic tissues on a chip for drug discovery. Drug Discov Today 2012;17:173–81
   PubMed Web of Science ®Google Scholar
• Kang L, Chung BG, Langer R, Khademhosseini A. Microfluidics for drug discovery and development: from target selection to product lifecycle management. Drug Discov Today 2008;13:1–13
   PubMed Web of Science ®Google Scholar
• Khademhosseini A, Langer R, Borenstein J, Vacanti JP. Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci USA 2006;103:2480–7
   PubMed Web of Science ®Google Scholar
• Khademhosseini A, Langer R. Drug delivery and tissue engineering. Chem Eng Prog 2006;102:38–42
   Web of Science ®Google Scholar
• Ling Y, Rubin J, Deng Y, et al. A cell-laden microfluidic hydrogel. Lab Chip 2007;7:756–62
   PubMed Web of Science ®Google Scholar
• Nguyen N-T, Shaegh SAM, Kashaninejad N, Phan D-T. Design, fabrication and characterization of drug delivery systems based on lab-on-a-chip technology. Adv Drug Deliv Rev 2013;65:1403–19
   PubMed Web of Science ®Google Scholar
• Riahi R, Tamayol A, Mousavi Shaegh SA, et al. Microfluidics for advanced drug delivery systems. Curr Opin Chem Eng 2015;7:101–12
   PubMed Web of Science ®Google Scholar
• Suh KY, Seong J, Khademhosseini A, et al. A simple soft lithographic route to fabrication of poly (ethylene glycol) microstructures for protein and cell patterning. Biomaterials 2004;25:557–63
   PubMed Web of Science ®Google Scholar